"Immunotoxins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant toxins, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect.
| Descriptor ID |
D000922
|
| MeSH Number(s) |
D12.776.124.790.651.114.580.450 D12.776.377.715.548.114.580.450 D27.888.569.271
|
| Concept/Terms |
Immunotoxins- Immunotoxins
- Cytotoxin-Antibody Conjugates
- Conjugates, Cytotoxin-Antibody
- Cytotoxin Antibody Conjugates
- Immunotoxin
- Antibody-Toxin Hybrids
- Antibody Toxin Hybrids
- Hybrids, Antibody-Toxin
- Affinotoxins
- Antibody-Toxin Conjugates
- Antibody Toxin Conjugates
- Conjugates, Antibody-Toxin
- Toxin-Antibody Conjugates
- Conjugates, Toxin-Antibody
- Toxin Antibody Conjugates
- Toxin-Antibody Hybrids
- Hybrids, Toxin-Antibody
- Toxin Antibody Hybrids
- Monoclonal Antibody-Toxin Conjugates
- Antibody-Toxin Conjugates, Monoclonal
- Conjugates, Monoclonal Antibody-Toxin
- Monoclonal Antibody Toxin Conjugates
Toxins, Chimeric- Toxins, Chimeric
- Chimeric Toxins
- Toxin Conjugates
- Conjugates, Toxin
- Toxin Carriers
- Carriers, Toxin
- Toxin Conjugate
- Conjugate, Toxin
- Chimeric Toxin
- Toxin, Chimeric
- Toxin Carrier
- Carrier, Toxin
|
Below are MeSH descriptors whose meaning is more general than "Immunotoxins".
Below are MeSH descriptors whose meaning is more specific than "Immunotoxins".
This graph shows the total number of publications written about "Immunotoxins" by people in this website by year, and whether "Immunotoxins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotoxins" by people in Profiles.
-
The D2D3 form of uPAR acts as an immunotoxin and may cause diabetes and kidney disease. Sci Transl Med. 2023 09 20; 15(714):eabq6492.
-
Mitigation of Hydrophobicity-Induced Immunotoxicity by Sugar Poly(orthoesters). J Am Chem Soc. 2019 03 20; 141(11):4510-4514.
-
Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group. J Immunother. 2015 Sep; 38(7):299-305.
-
Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol. 2012 Nov 10; 30(32):3921-3.
-
PEG-b-PPS-b-PEI micelles and PEG-b-PPS/PEG-b-PPS-b-PEI mixed micelles as non-viral vectors for plasmid DNA: tumor immunotoxicity in B16F10 melanoma. Biomaterials. 2011 Dec; 32(36):9839-47.
-
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007 Sep 01; 13(17):5144-9.
-
Epidermal growth factor receptor directed therapy in head and neck cancer. Crit Rev Oncol Hematol. 2006 Jan; 57(1):25-43.
-
Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease. Ann Oncol. 2004 Aug; 15(8):1231-6.
-
Thymic transplantation in miniature swine: III. Induction of tolerance by transplantation of composite thymokidneys across fully major histocompatibility complex-mismatched barriers. Transplantation. 2003 Aug 15; 76(3):530-6.
-
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002 Sep; 16(9):1627-36.